2026年A股首个交易日，市场一片热闹景象。 一方面，上证指数再度站上4000点，日线迎来罕见的12连阳。另一方面，权重股搭台，个股普涨，热点全面开花。 权重股方面，保险板块大涨；此外，贵州茅台（600519）、宁德时代（300750）、中芯国际等龙头股均上涨。板块方面，脑机接口、医药、半导体、消费 电子等板块大涨。 截至上午收盘，上证指数上涨1.07%，报4011.45点；深证成指上涨1.87%，创业板指上涨2.15%。 | 新华保险 融 601336 | 74.95 | 7.53% | 1563 Z | | --- | --- | --- | --- | | 中国太保 | 44.49 | 6.16% | 3045亿 | | 融 601601 | | | | | 行业龙头3 | | | | | 中国平安 ■ 601318 | 72.20 | 5.56% | 7697亿 | | 行业龙头2 | | | | | 中国人寿 融 601628 | 47.85 | 5.16% | 9964 Z | | 行业龙头1 | | | | | 中国人保 融 601319 | 9.38 | 4.80% | 3330亿 | 202 ...

Market Overview - The market opened high and continued to rise, with the Shanghai Composite Index returning to 4000 points after 34 trading days, and the ChiNext Index increasing by over 2% [1][2] - As of the morning close, the Shanghai Composite Index rose by 1.07%, the Shenzhen Component Index by 1.87%, and the ChiNext Index by 2.15% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [1][2] Sector Performance - The brain-computer interface concept saw a significant surge, with over twenty constituent stocks hitting the daily limit, including Sanbo Brain Science, Meihao Medical, Innovation Medical, Beiyikang, and Saili Medical [1][2] - The commercial aerospace sector remained active, with China Satellite Communications achieving three limit-ups in five days [1][2] - The insurance sector strengthened, with Xinhua Insurance and China Pacific Insurance both reaching historical highs [1][2] - The semiconductor industry chain showed robust performance, with Yaxiang Integration and Shenghui Integration hitting the daily limit [1][2] - Conversely, the Hainan Free Trade Zone concept experienced a collective decline, with Hainan Development hitting the daily limit down [1][2]

Group 1 - Major market indices opened higher on the first trading day of 2026, with electronics and media sectors rising over 2%, while pharmaceuticals and non-bank financials also showed strong gains [1] - The brain-computer interface (BCI) concept surged, with the index rising over 10%, leading to a wave of stock price increases, including a 30% limit up for BeiYikang and 20% limit ups for Sanbo Brain Science, Meihao Medical, and Aipeng Medical [2] - Elon Musk announced that his BCI company Neuralink will start large-scale BCI output in 2026, planning to shift towards nearly fully automated surgeries [3] Group 2 - Open Source Securities reported that Neuralink's expectations for scaled production and automated surgical solutions signify a transition from clinical validation to commercial scalability for brain-computer interfaces [4] - Companies with positive earnings forecasts for 2025 have performed well, with C Strong rising over 10% and Salt Lake Shares and Ocean Biological both increasing over 7%. Over 40 companies have released earnings forecasts, with many expecting profit increases, including Transfar Zhilian, Baiao Saitu, and Tianci Materials, all projecting profit growth exceeding 100% [5] - Ocean Biological expects a net profit growth of 50.6% to 72.56 million for 2025 [5] Group 3 - Two new stocks are available for subscription this week, including Zhixin Co., which specializes in automotive welding parts and has become a primary supplier for major automotive manufacturers [7] - Kema Materials focuses on the research, production, and sales of dry friction plates and wet paper-based friction plates, aiming to develop new friction materials [8] Group 4 - As of December 31, 2025, the market's financing balance totaled 2.52 trillion, a decrease of 143.69 billion from the previous trading day [9] - 349 stocks received net financing purchases exceeding 10 million, with 34 stocks having net purchases over 1 billion [10] - China Satellite topped the list with a net purchase of 1.194 billion, followed by Xinwei Communication and Aerospace Electronics with net purchases of 525 million and 499 million, respectively [11]

Market Overview - On the first day of the new year, the A-share market opened high and continued to rise, with the Shanghai Composite Index returning to 4000 points after 34 trading days, and the ChiNext Index increasing by over 2% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [1] Sector Performance - The brain-computer interface concept saw a significant surge, with over twenty constituent stocks hitting the daily limit, including Sanbo Brain Science, Meihao Medical, Innovation Medical, Beiyikang, and Saili Medical [3] - The commercial aerospace sector remained active, with China Satellite Communications achieving three limit-ups in five days [3] - The insurance sector strengthened, with Xinhua Insurance and China Pacific Insurance both reaching historical highs [3] - The semiconductor industry chain showed active performance, with stocks like Yaxiang Integration and Shenghui Integration hitting the daily limit [3] Declines - The Hainan Free Trade Zone concept experienced a collective decline, with Hainan Development hitting the daily limit down [4] - By the end of the trading session, the Shanghai Composite Index rose by 1.07%, the Shenzhen Component Index increased by 1.87%, and the ChiNext Index gained 2.15% [4]

Market Overview - The market opened higher on January 5, with the Shanghai Composite Index returning to the 4000-point level for the first time in 34 trading days, and the ChiNext Index rising over 2% [1] - By the midday close, the Shanghai Composite Index increased by 1.07%, the Shenzhen Component Index rose by 1.87%, and the ChiNext Index gained 2.15% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [1] Index Performance - Shanghai Composite Index: 4011.45, up 1.07% [2] - Shenzhen Component Index: 13777.32, up 1.87% [2] - ChiNext Index: 3272.07, up 2.15% [2] - North Star 50 Index: 1459.32, up 1.31% [2] Sector Highlights - Over 4000 stocks in the market experienced gains, with 98 stocks hitting the daily limit [2] - The brain-computer interface sector saw significant activity, with over twenty constituent stocks hitting the daily limit, including Sanbo Brain Science, Meihao Medical, and Innovation Medical [2] - The commercial aerospace sector remained active, with China Satellite Communications achieving three consecutive trading limits in five days [2] - The insurance sector strengthened, with Xinhua Insurance and China Pacific Insurance both reaching historical highs [2] - The semiconductor industry chain showed robust performance, with stocks like Yaxiang Integration and Shenghui Integration hitting the daily limit [2] - Conversely, the Hainan Free Trade Zone concept stocks collectively declined, with Hainan Development hitting the daily limit down [2]

（原标题：A股午评：沪指收复4000点大关！创业板指涨2.15%，脑机接口概念现涨停潮） 盘面上，脑机接口概念大面积涨停，创新医疗、三博脑科、美好医疗等超20股涨停，马斯克旗下 Neuralink将开始大规模生产脑机接口设备。保险板块大涨，中国太保、新华保险双双创新高。存储芯 片、贵金属、商业航天等板块走强，海南自贸区板块回调。 2026年首个A股交易日，三大指数强势大涨，截至午间收盘，沪指涨1.07%报4011.45点，深成指涨 1.87%，创业板指涨2.15%，北证50指数涨1.31%。沪深京三市半日成交额16489亿元，较上日放量3240 亿元，全市场超4000只个股上涨。 ...

Core Viewpoint - The medical sector is experiencing a strong performance, with the largest medical ETF (512170) showing significant gains, driven by positive market sentiment and news regarding Neuralink's plans for large-scale production of brain-computer interface devices starting in 2026 [1][3]. Group 1: Market Performance - On January 5, 2026, the medical ETF (512170) opened high and rose over 4%, potentially marking the largest single-day gain in nearly three months, with real-time transactions exceeding 650 million yuan [1]. - All 50 constituent stocks of the medical ETF saw increases, with notable surges in brain-computer interface stocks, including Sanbo Brain Science, Meihua Medical, and Lepu Medical, which hit the daily limit of 20% [1]. - The CXO sector also performed strongly, with Zhaoyan New Drug reaching the daily limit and WuXi AppTec increasing by nearly 6% [1]. Group 2: Fund and Index Details - The medical ETF (512170) has a total scale exceeding 25.259 billion yuan, making it the largest medical and healthcare ETF in the market, serving as a significant industry benchmark [3]. - The ETF focuses on "medical devices + medical services," with a CXO weight exceeding 26%, and includes leading companies in aesthetic medicine, private hospitals, and medical information technology [3]. - The current price-to-earnings ratio of the underlying index for the medical ETF is 32 times, which is lower than over 70% of the time in the past decade, indicating a favorable cost-performance ratio for investors [1].

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

政策端也持续加码支持。国家药监局近期在北京召开脑机接口医疗器械工作推进会，明确表示将加快相 关产品的审评审批流程，推动创新器械更快上市应用。 国金证券指出，在医疗器械创新政策密集落地 背景下，脑机接口作为前沿交叉领域，正迎来从科研验证向临床及消费场景拓展的关键窗口期。 （文章来源：每日经济新闻） 医疗器械ETF（562600）大涨4.36%。截止2025年12月30日，医疗器械ETF脑机接口含量达20.91%。 消息面上，行业迎来多重催化。特斯拉CEO埃隆·马斯克近日在社交媒体透露，其旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备的"大规模生产"。这一表态被市场视为该技术迈向商业化的重 要信号。 与此同时，由OpenAI首席执行官Sam Altman联合创立的脑机接口初创公司Merge Labs宣布将分拆为独 立实体，专注于开发基于超声波的非侵入式脑信号读取技术。该方案无需植入电极，即可实现对大脑活 动的大范围、高精度解读，有望大幅降低技术门槛与临床风险。 早盘脑机接口概念小幅高开，随后震荡上行，截止10点57分，乐普医疗、美好医疗、翔宇医疗、伟思医 疗、迈普医学封板涨停。 ...

2026年A股开盘首日，脑机接口概念表现活跃。截至发稿，倍益康30CM涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通、伟思医疗20cm 涨停，创新医疗、南京熊猫10CM涨停，博拓生物、狄耐克等涨超10%。 开源证券最新研报表示， 上述行业事件印证了脑机接口技术预计将在2026年迈向商业化，并从医疗刚需向AI应用、机器人等多领域渗透 。 Neuralink的规模化生产预期+自动化手术方案，以及Merge布局新一代超声波脑机接口技术具备双重意义。一方面，这标志着脑机接口从临 床验证阶段开始向商业化规模化阶段迈进，推动脑机接口从"医疗试验工具"到"可普及产品"的落地；另一方面，未来随着技术方案成熟度的 进一步提升，也将为Neuralink脑机接口与特斯拉Optimus人形机器人的协同应用奠定基础。 该机构进一步表示，脑机接口行业正处于技术突破、政策支持、机器人生态协同预期等多重因素驱动下的高增蓄势期，根据Precedence Research数据， 预计到2034年全球脑机接口市场规模将增长到约124亿美元 ，2025-2034年CAGR为17%。 在近期Neuralink规模化量 产预期和技术突破的催化下， ...